Sleep MedicineSeptember 16, 2026Abanoub J Armanious, Alexandra R Dunn, Caitlin E Martin et al.
Lemborexant is a dual orexin receptor antagonist (DORA) approved for the clinical management of insomnia. Clinical trials indicate that lemborexant improves sleep onset latency and sleep maintenance, with mild somnolence as the most common side effect. However, there is limited real-world evidence characterizing patient experiences with lemborexant, including perceived benefits, side effects,...
Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have contributed to this paucity, including the biological complexity of addiction, regulatory challenges, and a historical lack of enthusiasm among pharmaceutical companies to commit resources to this disease space. Despite these headwinds, the recent...